Victor Ovalle Marrero, PA
Physician Assistant · Cincinnati, OHNPI 1922735992
Payments from drug & device makers
Across 212 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$644
- Urogen Pharma, Inc.$480
- Johnson & Johnson$449
- Astellas Pharma US Inc$380
- Dendreon Pharmaceuticals LLC$336
- Teleflex LLC$317
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$1242%
- Food & beverage$5,44897%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 29 | $644 |
| Urogen Pharma, Inc. | 21 | $480 |
| Johnson & Johnson | 19 | $449 |
| Astellas Pharma US Inc | 19 | $380 |
| Dendreon Pharmaceuticals LLC | 8 | $336 |
| Teleflex LLC | 4 | $317 |
| Boston Scientific | 3 | $301 |
| Novartis | 8 | $224 |
| Ferring Pharmaceuticals Inc. | 9 | $223 |
| Bayer | 13 | $218 |
| Calyxo, Inc. | 3 | $206 |
| Procept Biorobotics Corporation | 2 | $196 |
| Axonics, Inc. | 5 | $188 |
| Immunitybio, Inc. | 8 | $174 |
| Merck | 6 | $141 |
| Medtronic | 2 | $140 |
| Endo Pharmaceuticals Inc. | 7 | $140 |
| 180 Medical, Inc. | 4 | $116 |
| Antares Pharma, Inc. | 6 | $112 |
| Olympus America Inc. | 4 | $78 |
| Sun Pharmaceutical Industries Inc. | 3 | $63 |
| Halozyme Inc | 3 | $57 |
| Progenics Pharmaceuticals, Inc. | 3 | $53 |
| AstraZeneca | 3 | $51 |
| Baxter Healthcare | 2 | $39 |
| Myovant Sciences Inc. | 2 | $33 |
| Endo USA, Inc. | 1 | $31 |
| Pfizer | 2 | $29 |
| Angiodynamics, Inc. | 2 | $29 |
| Accord Healthcare, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Telix Pharmaceuticals | 1 | $19 |
| Coloplast | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Photocure Inc | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$271
- Axonics$267
- CVAC Aspiration System$161
- PROVENGE$145
- GENERAL ERECTILE DYSFUNCTION$144
- GEMTESA$124
- Erleada$122
- AQUABEAM SYSTEM$121
- INTERSTIM$120
How this compares
$5,640 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 75 | $60,835 |
| GemtesaVibegron | 40 | $28,280 |
| Tamsulosin Hcl | 334 | $3,782 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 59 | $951 |
| Finasteride | 119 | $921 |
| Estradiol | 13 | $839 |
| NitrofurantoinNitrofurantoin Macrocrystal | 16 | $491 |
| Cephalexin | 33 | $239 |
| Ciprofloxacin Hcl | 47 | $214 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $196 |
| Nystatin | 11 | $170 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $123 |
| Fluconazole | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $380 | $60,83575 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $644 | $28,28040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Cincinnati
- Steven WurzelbacherCincinnati$309K
- Alan OdonnellCincinnati$71K
- Melissa DoveCincinnati$41K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.